Metoprolol Succinate Extended-Release Tablets Recalled for Storage Temperature Deviations
Cardinal Healthcare is recalling Metoprolol Succinate Extended-Release Tablets (50 mg) nationwide. Batch 2447J211 was exposed to temperatures outside labeled storage conditions, which could compromise medication effectiveness.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The FDA classified this as a Class II recall due to CGMP deviations from improper storage temperatures. Although no illnesses or injuries have been reported, temperature exposure of a cardiac medication creates a theoretical risk of reduced effectiveness. The score reflects this risk without confirmed adverse events.
Plain-English summary
Cardinal Healthcare is recalling Metoprolol Succinate Extended-Release Tablets, 50 mg (NDC 45963-676-96), distributed nationwide. The recalled batch is 2447J211.
The recall was initiated due to a Good Manufacturing Practice (CGMP) deviation. Products in the affected batch were exposed to temperatures outside the labeled storage conditions. This exposure may have compromised product quality and effectiveness.
Patients currently taking this medication should contact their healthcare provider or pharmacist regarding their specific situation and medication supply.
The recalled product
- Product
- METOPROLOL SUCCINATE (METOPROLOL SUCCINATE)
- Brand
- METOPROLOL SUCCINATE
- Manufacturer
- CARDINAL HEALTHCARE
- Category
- Drug
- Hazard
- improper-storage
- potency-degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Batch 2447J211
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · METOPROLOL SUCCINATE
- ModerateMetoprolol Succinate Extended-Release Tablets Recalled Due to Failed Dissolution
FDA (Drugs) · 2026-05-20
- HighMetoprolol Succinate ER Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2023-02-22
- HighMetoprolol Succinate Extended-Release Tablets Recalled for Failed Dissolution Specification
FDA (Drugs) · 2023-02-01
- ModerateMetoprolol Succinate Tablets Recalled for Failed Dissolution Specification
FDA (Drugs) · 2023-02-01
- HighPrescription Metoprolol Succinate Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-02-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateClomiphene Citrate USP Active Pharmaceutical Ingredient Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-15
- SevereBortezomib for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- ModerateGasco Isopropyl Alcohol 70% recalled nationwide for subpotency
FDA (Drugs) · 2026-07-15